ArticleJournal of oral & facial pain and headache2025
Combination effect of ultrasound-guided superior cervical ganglion block and standard triptan for migraine attacks.
Article in Journal of oral & facial pain and headache, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Automated segmentation and quantitative measurement of cervical nerves in ultrasound images using an SZJ-SEG-based deep learning framework.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo examine whether the combination of ultrasound (US)-guided superior cervical ganglion (SCG) block with standard triptans has a superior relief of headache as compared to triptans alone for acute migraine.
methodsThe retrospective-prospective cohort study enrolled patients presenting with acute migraine. The records of 243 cases receiving standard triptans and an adjunctive US-guided SCG were reviewed, while 230 cases were prospectively enrolled to receive triptan alone for control after age and sex matching in a 1:1.2 ratio. The primary endpoint was sustained headache relief and complete freedom from pain within post-procedural 24 hours. Secondary outcomes included headache relief and freedom from pain at 2 hours, monthly migraine days (MMDs), migraine disability assessment (MIDAS) scores, migraine-specific quality of life questionnaire (MSQ) scores, need for rescue analgesics use and adverse events.
resultsSustained headache relief was observed in 69.5% of cases in the SCG cohort, yielding a superior outcome increased by 21.7% (95% confidence interval (CI): 13.1%, 30.4%) (
conclusionsThere was a superior therapeutic effectiveness of US-guided SCG block in conjunction with standard triptans for better headache relief up to post-procedural 1 month in acute migraine. It had an adjunctive beneficial effect in functional ability, life quality and possible facilitation of avoiding more adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.